You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
A 412997 dihydrochloride
Biological Activity for A 412997 dihydrochloride
A 412997 dihydrochloride is a selective agonist for the dopamine D4 receptor (Ki values are 7.9 and 12.1 nM for human D4 and rat D4 receptors). Displays no affinity (<1000 nM) for other dopamine receptors. Shows efficacy in rat models of ADHD and short-term memory.
Compound Libraries for A 412997 dihydrochloride
Technical Data for A 412997 dihydrochloride
|Storage||Desiccate at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for A 412997 dihydrochloride
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions for A 412997 dihydrochloride
The following data is based on the product molecular weight 382.33. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.62 mL||13.08 mL||26.16 mL|
|5 mM||0.52 mL||2.62 mL||5.23 mL|
|10 mM||0.26 mL||1.31 mL||2.62 mL|
|50 mM||0.05 mL||0.26 mL||0.52 mL|
Product Datasheets for A 412997 dihydrochloride
References for A 412997 dihydrochloride
References are publications that support the biological activity of the product.
Browman et al (2005) A-412997, a selective DA D4 agonist, improves cognitive performance in rats. Pharmacol.Biochem.Behav. 82 148 PMID: 16154186
Patel et al (2006) Discovery of 3-methyl-N-(1-oxy-3',4',5',6'-tetrahydro-2'H-[2,4'-bipyridine]-1'-ylmethyl)benzamide (ABT-670), an orally bioavailable DA D4 agonist for the treatment of erectile dysfunction. J.Med.Chem. 49 7450 PMID: 17149874
Moreland et al (2005) A-412997 is a selective DA D4 receptor agonist in rats. Pharmacol.Biochem.Behav. 82 140 PMID: 16153699
If you know of a relevant reference for A 412997 dihydrochloride, please let us know.
View Related Products by Product Action
Keywords: A 412997 dihydrochloride, A 412997 dihydrochloride supplier, A412997, selective, agonists, dopamine, dopaminergic, d4, D4, Receptors, 4552, Tocris Bioscience
Citations for A 412997 dihydrochloride
Citations are publications that use Tocris products.
Currently there are no citations for A 412997 dihydrochloride. Do you know of a great paper that uses A 412997 dihydrochloride from Tocris? Please let us know.
Reviews for A 412997 dihydrochloride
There are currently no reviews for this product. Be the first to review A 412997 dihydrochloride and earn rewards!
Have you used A 412997 dihydrochloride?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Dopamine Receptors Scientific Review
Written by Phillip Strange and revised by Kim Neve in 2013, this review summarizes the history of the dopamine receptors and provides an overview of individual receptor subtype properties, their distribution and identifies ligands which act at each receptor subtype. Compounds available from Tocris are listed.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.